The guide

ApoB on a statin

By GyroscopeUpdated November 15, 20266 sources

Your prescriber decides any change to your treatment. This page reports what the 2026 US guideline and the research say. Keep taking your medicine as prescribed, and never stop or change it on your own.

Statins lower ApoB less than they lower LDL, about 33% against 42% on average across 11 trials. That means your LDL can reach its goal while your ApoB doesn’t. The 2026 US guideline says checking ApoB at that point is reasonable, to decide whether to do more. Take both numbers to the person who prescribes your medicine.

Why LDL at goal can still leave ApoB high

A statin makes your liver put out more receptors, which pull particles out of the blood. The National Lipid Association’s 2024 consensus says treatment tends to clear the larger, more cholesterol-rich LDL particles first. The particles left behind carry less cholesterol each, so your LDL falls further than your particle count.

Across 11 trials, 9 with a statin alone and 2 with a statin plus ezetimibe, the NLA found ApoB fell 33% on average and LDL fell 42%. From an LDL of 100 and an ApoB of 100, that’s an LDL of 58 and an ApoB of 67.

Picture thinning a crowd by asking the people carrying the most bags to leave first. The number of bags drops fast. The number of people drops more slowly. LDL counts the bags, and ApoB counts the people.

A worked example

Take someone with a stent, on a statin, with an LDL of 52 and an ApoB of 88. Their LDL is under its goal of 55. Their ApoB is 28 points over the rung of under 60 that the National Lipid Association matches to that goal. That’s exactly the situation the guideline’s recommendation describes.

The biggest single food change measured for ApoB takes off about 7 points. A 28 point gap is a conversation with the prescriber, with the food changes running alongside whatever they decide.

What the studies show on treatment

In Copenhagen, 13,015 people on statins were followed for about 8 years. Those whose ApoB was above the group’s median while their LDL was below it had 1.49 times the heart attacks and 1.21 times the deaths of people with both below. A high LDL with a low ApoB wasn’t linked to more of either.

In 40,430 people with heart disease on statins from clinical trials, analysed with 389,529 UK Biobank adults, “only apoB” stayed tied to heart attacks once the other lipids were in the same model.

What the 2026 guideline says

• The recommendation (class 2a, “reasonable”): “In adults on LLT, particularly those with ASCVD, CKM syndrome, type 2 diabetes, and/or elevated TG, measurement of apoB is reasonable to guide decisions regarding further therapeutic intensification once LDL-C and/or non–HDL-C goals are achieved.” LLT means lipid-lowering therapy, and ASCVD means heart attacks, strokes and other artery disease.
• Who gains most: the guideline’s summary names triglycerides over 200 mg/dL, diabetes and an LDL brought under 70.
• A goal of its own: for people with heart disease and severe high cholesterol, once their LDL and non-HDL goals are met, it says it “may be reasonable” to check ApoB with a goal of under 55 mg/dL.
• How often: a lipid profile 4 to 12 weeks after a medicine is started or increased, then every 6 to 12 months.

The medicines the guideline names

The guideline says ApoB can help decisions about nonstatin medicines, and names four: ezetimibe, bempedoic acid, the PCSK9 antibodies and inclisiran. The NLA’s consensus sizes two of them for ApoB. Adding ezetimibe to a statin lowered ApoB a further 15% in a large trial, and adding a PCSK9 antibody lowered it more than 40%. Which, if any, suits you depends on things only your prescriber knows, like your other conditions, your other medicines and your coverage.

Fish oil isn’t one of them. The guideline recommends against supplements for lowering cholesterol, and notes that prescription omega-3 esters “can modestly raise LDL-C (but not apoB)”.

Questions to bring

1. What’s my ApoB goal? Ask which risk band you’re in. Under 60, 70 or 90 follows from it.
2. Is my LDL calculated, and with which formula? The guideline prefers the newer Martin/Hopkins or Sampson/NIH methods, which disagree with ApoB less often than the old one.
3. Should we recheck ApoB in 4 to 12 weeks? It’s the window the guideline uses after a change.
4. Could something else be raising it? The guideline’s list of causes includes an underactive thyroid, kidney and liver disease, diabetes and some medicines.

Food changes still add to a medicine, if you want to and can. How do I lower ApoB naturally? has the plan, and Should I take a statin for a high ApoB? has the case for and against.

The fight

The guideline’s recommendation is graded on evidence from studies that followed people, not from trials. Nobody has randomly assigned people to treatment aimed at an ApoB goal and compared heart attacks with treatment aimed at an LDL goal. A 2026 computer model from Northwestern University suggested that ApoB-guided treatment would prevent more heart attacks and strokes, and the trial to test it hasn’t been done. We think the case is strong enough to check ApoB once LDL is at goal, and to let your prescriber decide what to do with it.

Before you change anything, talk to the person who prescribed your medicine. Never stop a cholesterol medicine on your own.